Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06801353

A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps

Status
Not Yet Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Beijing Tongren Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Recently, several biologic therapies have become available for treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, not every patient responds to these treatments. This clinical trial aims to develop a non-invasive predictive model to help determine how effective IL-4Rα targeted monoclonal antibody therapy will be for individuals with CRSwNP.

Conditions

Interventions

TypeNameDescription
BIOLOGICALStapokibartStapokibart subcutaneously every two weeks
DRUGMometasone Furoate Nasal Spray (MFNS)mometasone furoate nasal spray 200 μg once daily

Timeline

Start date
2025-02-01
Primary completion
2025-12-01
Completion
2026-07-01
First posted
2025-01-30
Last updated
2025-02-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06801353. Inclusion in this directory is not an endorsement.

A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps (NCT06801353) · Clinical Trials Directory